Literature DB >> 2172193

Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients.

Y Inoue1, N Shijubo, T Uede.   

Abstract

We analyzed the phenotype and cytotoxic ability of pleural exudative lymphocytes (PLEL) which were obtained from 18 advanced lung cancer patients. Freshly isolated PLEL were mainly CD4(+) T cells and had weak natural killer, autologous tumor killing and lymphokine-activated killer activities. After cultivation of PLEL with interleukin-2, cytotoxicity of PLEL against autologous tumor cells was increased at 2 weeks, but it was remarkably reduced at 4 weeks. When PLEL were stimulated by mitomycin C-treated autologous tumor cells during culture, autologous tumor killing activity of PLEL was significantly enhanced even after 4 weeks of cultivation. Cold target inhibition analysis and binding inhibition assays using monoclonal antibodies indicated that autologous tumor stimulation could induce major histocompatibility complex class I restricted cytotoxic T lymphocytes specific for autologous tumor cells in some cases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172193      PMCID: PMC5917975          DOI: 10.1111/j.1349-7006.1990.tb03339.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Authors:  J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

2.  Functional analysis of mononuclear cells infiltrating into tumors. IV. Purification and functional characterization of cytotoxic cell-generating factor.

Authors:  T Murakami; T Uede; N Shijubo; Y Torimoto; T Ide; K Sugimura; I Azuma; Y Takai; K Kikuchi
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

3.  Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

Authors:  A Belldegrun; A Kasid; M Uppenkamp; S L Topalian; S A Rosenberg
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

4.  Functional analysis of mononuclear cells infiltrating into tumors. II. Differential ability of mononuclear cells obtained from various tissues to produce helper factors that are involved in the generation of cytotoxic cells.

Authors:  T Uede; H Kohda; Y Ibayashi; H Osawa; T Diamantstein; K Kikuchi
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

5.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

6.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

7.  Functional analysis of mononuclear cells infiltrating into tumors. V. A. soluble factor involved in the regulation of cytotoxic/suppressor T cell infiltration into tumors.

Authors:  N Shijubo; T Uede; K Kikuchi
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

8.  Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.

Authors:  D K Blanchard; J J Kavanagh; J G Sinkovics; D Cavanagh; S M Hewitt; J Y Djeu
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

9.  The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice.

Authors:  P R Twentyman; P Workman; K A Wright; N M Bleehen
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

10.  Functional analysis of mononuclear cells infiltrating into tumors: establishment of a new system to obtain functionally active tumor-infiltrating cells.

Authors:  N Shijubo; T Uede; N Nomura; K Kikuchi
Journal:  Jpn J Cancer Res       Date:  1990-01
View more
  3 in total

1.  Prognostic value of CD4+ lymphocytes in pleural cavity of patients with non-small cell lung cancer.

Authors:  K Takahashi; S Saito; Y Kamamura; M Katakawa; Y Monden
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

2.  Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines.

Authors:  M Hirasawa; N Shijubo; T Uede; S Abe
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

3.  Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.

Authors:  Ryota Horibe; Yoshihiko Hirohashi; Takuya Asano; Tasuku Mariya; Takeshi Suzuki; Akari Takaya; Hiroshi Saijo; Yosuke Shionoya; Terufumi Kubo; Munehide Nakatsugawa; Takayuki Kanaseki; Tomohide Tsukahara; Kazue Watanabe; Eri Atsuyama; Shingo Toji; Hiroshi Hirano; Tadashi Hasegawa; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.